China Original PADN Multi -Center Studies were released globally for the first time!Ten years of sharpening, the first hospital created the three world business cards of medical innovation

From September 16th to 19th, the world's largest and influential US Economic Conduct Cardiovascular Cardiovascular Treatment Academic Conference (TCT 2022) was grandly held in Boston and lived to the world online. On September 18th, Beijing time, Professor Chen Shaoliang, deputy dean of Nanjing First Hospital and director of the Department of Cardiology, announced the first announcement of clinical research on the treatment of pulmonary hypertension (PADN-CFDA) for the treatment of dermatology.

It is understood that pulmonary hypertension is a disease that increases pulmonary vascular resistance, leading to a disease with right heart functional incompleteness. The main symptoms are the shortage, fatigue, and edema of unknown causes. The disease involves many diseases, the pathogenesis mechanism is complicated, the diseased group is young, and the treatment methods are limited. Therefore, it is called "cancer of the cardiovascular system". The 5 -year survival rate is only 20.8%under the premise of no targeted drug treatment. Therefore, although "niche", the "lethality" is amazing.

Ten years ago, Professor Chen Shaoliang first reported the results of PADN-1 for the first time at the TCT2012 conference. For the first time, pulmonary deodorization (PADN) was first displayed in front of the world, attracting global cardiovascular intervention and the attention of pulmonary hypertension experts. Pattius deodorization (PADN) is a pulmonary hypertension intervention therapy technology independently developed by Professor Chen Shaoliang. It has obtained the patent and methodology of invention and methodology of nearly 50 countries around the world. This is a minimally invasive interventional treatment method that uses radio frequency anti -fusion to block the endometrial intraocular sympathetic nerve and reduce the pressure of pulmonary arteries, thereby treating pulmonary hypertension or delaying the progress of the disease.

In ten years, PADN-1 PHASE Ⅰ, Padn-PHASE Ⅱ, Padn-5 studies carried out by Professor Chen Shaoliang's team have been announced one after another, providing more evidence-based medical evidence for the security and effectiveness of PADN technology. The FDA breakthrough therapy certification has won widespread attention around the world.

In August 2022, the annual meeting of the European Cardiology Society released the "2022 ESC/ERS pulmonary hypertensive diagnosis and treatment guide", which provided the best plan for the diagnosis and treatment of global lung hypertension and the latest evidence support. The new version of the "Guide" introduced the treatment of pulmonary hypertension intervention in the treatment of pulmonary arterial hypertension intervention therapy. Professor Chen Shaoliang, Professor of Nanjing First Hospital, Pa De Ervation (PADN), which fully affirmed that PADN technology has presented in the field of pulmonary hypertension treatment. The important academic value and clinical potential of the technology also reflect the positive significance of this technology for the cure and health management of patients with pulmonary hypertension.

During the TCT2022 conference, Professor Chen Shaoliang brought PADN-CFDA research results to the stage of the TCT conference again to show the academic charm of Chinese original technology and original research, and let the world listen to Chinese voices.

Correspondent Peng Hongjuan Zhang Chen

Nanjing Morning Post/Ai Nanjing reporter Qi Zaibing

- END -